A VLP-based vaccine provides complete protection against Nipah virus challenge following multiple-dose or single-dose vaccination schedules in a hamster model

Abstract

Nipah virus: Virus-like particles protect against major public health concern A vaccine candidate consisting of virus-like particles could offer the first effective prophylaxis against the deadly Nipah virus. Endemic to Malaysia, Bangladesh, and India, Nipah virus is contracted from infected fruit bats and causes severe inflammation of the brain. Pramila Walpita, of the University of Hawaii, working with colleagues at the United States’ National Institute of Allergy and Infectious Diseases, developed an effective vaccine of immunity-generating Nipah virus surface proteins without the virus’ disease-causing genetic material. Their vaccine elicited a significant protective antibody response, with 100% of vaccinated animals surviving subsequent Nipah virus infection. Despite its prevalence and lethality, Nipah virus has no licensed vaccine and poses a serious problem to the developing countries it affects. Walpita’s vaccine candidate could offer a much-needed treatment option and warrants further investigation and pre-clinical trials.